As for other CNS tumours, further advances in deep-learning radiomics analysis of craniopharyngiomas could help in the future in avoiding biopsies, predicting the presence of BRAF mutation before surgery and thus favouring the use of targeted therapies as a neoadjuvant regimen [43,44,45]. This evidence concerns the gene BRAF and craniopharyngioma.